LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune checkpoint inhibitors targeting programmed cell death-ligand 1 (PD-L1) show efficacy in hepatocellular carcinoma (HCC).
• Tumor cells often evade immune surveillance via PD-L1 overexpression, but its regulation in HCC is unclear.
• Understanding PD-L1 regulation is crucial for overcoming immunotherapy resistance in HCC.

Purpose of the Study:

• To investigate the regulatory mechanisms of PD-L1 overexpression in HCC.
• To identify novel therapeutic targets for enhancing HCC immunotherapy.
• To explore strategies to overcome resistance to PD-L1 inhibitors in HCC.

Main Methods:

• Integrated analysis of single-cell transcription sequence data.
• Functional characterization of Lamin B2 (LMNB2) as a transcriptional regulator of PD-L1.
• Investigation of speckle-type POZ protein (SPOP) interaction with LMNB2.
• In vitro and in vivo studies of combinatorial therapy targeting LMNB2 and PD-L1.

Main Results:

• Aberrant LMNB2 upregulation was identified in immunotherapy-sensitive HCC patients.
• LMNB2 directly regulates PD-L1 expression, promoting immune escape.
• SPOP mediates LMNB2 ubiquitination and degradation, controlling PD-L1 levels.
• SPOP mutations or reduced expression lead to LMNB2 accumulation and PD-L1 hyperactivation.
• Combinatorial targeting of LMNB2 and PD-L1 showed synergistic tumor suppression.

Conclusions:

• A novel ubiquitination-dependent regulatory axis involving LMNB2 and SPOP controls PD-L1 expression in HCC.
• This axis represents a key mechanism for HCC immune evasion.
• Targeted co-inhibition strategies, particularly in SPOP-mutated or LMNB2-overexpressing HCC, hold promise for overcoming immunotherapy resistance.